MOTS‑C is a mitochondria‑derived peptide that improves metabolic homeostasis, insulin sensitivity and exercise performance, and users employ it chiefly for exercise performance, obesity management and metabolic health. Community users most often take around 2 mg per day (with a wide range of 0.5 mg–40 mg) and frequently follow a 5‑days‑on/2‑days‑off schedule, while clinician protocols tend to prescribe 5 mg daily subcutaneously for 4‑ to 6‑week cycles. The biggest caveat is that the off‑label evidence base is thinner than the discussion implies, with most exploratory indications lacking posted results.
Data last updated
Measured on 5 of 6 axes
Evidence shape
The evidence for MOTS‑c is low, with only a single published diagnostic/mechanistic study and a recruiting trial in prediabetes providing any human data. Across the three indications mapped, the depth shows one registered trial that is recruiting, but there are no completed trials and only exploratory data from two thin/exploratory (prediabetes and diagnostic/mechanistic) and one animal‑only indication, plus two single‑trial long‑tail entries that lack posted results. Both human indications rely on one trial each without results, while the animal‑only indication has no human data.
Efficacy signal
Completed studies are present, but primary-endpoint pass/fail classification is not yet clean enough to score. These are the currently projected indication-level signals.
Prediabetes
1 study
Diagnostic & mechanistic studies
1 study
No completed study rows are available for endpoint scoring yet.
Human evidence
Lower-tier support
Published literature
Standalone PubMed / Europe PMC publications matched to this peptide and deduped by identifier. Trial records and animal / in-vitro rows are surfaced above; these are the human-relevant papers behind them.
Source data
Clinical research side effects
Clinical safety table not projected yet.
Anecdotal side effects
price offers can be sorted by column · 31 out-of-stock offers not shown
How MOTS-C is dosed across research, clinician, and community sources — each evidence tier kept separate so the dose range, frequency, timing, and cycling stay visible without flattening different levels of evidence.
No structured protocol details captured for this tier yet.
This tier has no reliably captured dosing information; zero completed trials were identified, so no amount, frequency, or cycling can be stated.
Two sources agree on a 5 mg subcutaneous injection taken daily, with no cycling protocol specified, and the dosing pattern is consistent across the available clinician reports.
Most users give no fixed schedule; among those who do, weekly and daily dosing are common, typically around 2 mg per injection. A small subset (6 reports) follow a 5‑days‑on/2‑days‑off cycle.